Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Disability evaluation under social security (hematological disorders-adult)
source: Social Security Administration
year: N/A
summary/abstract:A. What hematological disorders do we evaluate under these listings?
– We evaluate non-malignant (non-cancerous) hematological disorders, such as hemolytic anemias (107.05), disorders of thrombosis and hemostasis (107.08), and disorders of bone marrow failure (107.10). These disorders disrupt the normal development and function of white blood cells, red blood cells, platelets, and clotting-factor proteins (factors).
– We evaluate malignant (cancerous) hematological disorders, such as lymphoma, leukemia, and multiple myeloma, under the appropriate listings in 13.00, except for two lymphomas associated with human immunodeficiency virus (HIV) infection. We evaluate primary central nervous system lymphoma associated with HIV infection under 114.11B, and primary effusion lymphoma associated with HIV infection under 114.11C.
B. What evidence do we need to document that you have a hematological disorder?
We need the following evidence to document that you have a hematological disorder:
– A laboratory report of a definitive test that establishes a hematological disorder, signed by a physician; or
– A laboratory report of a definitive test that establishes a hematological disorder that is not signed by a physician and a report from a physician that states you have the disorder.
+myBinderRelated Content
-
An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomesOBJECTIVE: To identify characteristics ...
-
Venous thromboembolism in adults screened for sickle cell trait: a population-based cohort study with nested case-co...OBJECTIVE: To determine whether sickle ...
-
Advances in the Treatment of Sickle Cell Disease: L-Glutamine, Crizanlizumab & Gene Therapyhttps://www.youtube.com/watch?v=wkm4axJ3...
-
Possible Cure for Sickle Cell Found in ParisHematologists, sickle cell patients, and...
-
Gene therapy may help cure sickle cell disease, study saysA gene therapy that could provide a perm...
-
Progress in pursuit of sickle cell cureBao, in collaboration with Baylor Colleg...
-
Sickle cell patient with severe anemia rapidly improves with voxelotor, case study showsGlobal Blood Therapeutics (GBT) reported...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.